1,4-Dibromobutane | CAS:110-52-1

We serve 1,4-Dibromobutane CAS:110-52-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1,4-Dibromobutane

Chemical Name:1,4-Dibromobutane
CAS.NO:110-52-1
Synonyms:1,4-Dibromobutane
1,4-dibromo-butan
Molecular Formula:C4H8Br2
Molecular Weight:215.91400
 
Physical and Chemical Properties:
Density:1.808
Melting point:-20ºC
Boiling point:63-65ºC
Flash point:>230°F
Index of Refraction:1.519
 
Specification:
Appearance:Colorless to pale yellow transparent liquid
Assay:≥9.0%
Moisture:≤0.5%
 
Packing:250 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 1,4-Dibromobutane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,4-dibromo-butan physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,4-Dibromobutane Use and application,1,4-Dibromobutane technical grade,usp/ep/jp grade.


Related News: Australia’s ban followed an earlier move by the US Friday to deny entry to foreign nationals who have traveled in China in the last 14 days.(3S,4S)-3-Hexyl-4-[(2S)-2-hydroxytridecyl]-2-oxetanone manufacturer Since the listing of high-barrier generic drugs involves quickly bypassing or challenging process patents of original research products within a short period of time, API companies play an important role in the process of marketing and sales of generic drugs.1-bromo-7-fluoroheptane supplier Some experts said that in the research and development of chemical medicine, the possibility of large medicines is getting smaller and smaller, and with the popularization of precision treatment, small medicines (high-efficiency medicines) are being introduced more and more.N-Hydroxymethyl-3,4,5,6-tetrahydrophthalimide vendor Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.Genzyme Pharmaceuticals develops and manufactures chemically synthesized pharmaceutical materials and technologies for the global pharmaceutical industry and focuses on lipids, peptides, carbohydrates, oligonucleotides, and custom small molecules.